Skip to main content
ADBIOTECH Co.,Ltd. logo

ADBIOTECH Co.,Ltd. — Investor Relations & Filings

Ticker · 179530 ISIN · KR7179530001 KO Manufacturing
Open in API
Filings indexed 416 across all filing types
Latest filing 2023-12-27 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 179530

About ADBIOTECH Co.,Ltd.

http://www.adbiotech.com

ADBIOTECH Co., Ltd. is a biotechnology company specializing in the development and commercialization of immune antibodies. The company's core competency is IgY (Immunoglobulin in Yolk) technology, which utilizes antibodies derived from eggs to create alternatives to conventional vaccines and antibiotics. Its product portfolio targets the livestock, aquaculture, and human health sectors, with applications for disease prevention and treatment in animals like salmon and shrimp, as well as human-focused developments for conditions related to Helicobacter pylori and cholesterol. The company manages the entire value chain from research and development to production and sales. ADBIOTECH is also expanding its technological capabilities into VHH (nanobody) technology, with a strategic focus on the global companion animal market.

Recent filings

Filing Released Lang Actions
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and is a correction (정정신고) to a previous filing. It details changes to stock option grants, including the number of shares and the list of recipients. In the context of corporate filings, stock option grants and their subsequent amendments are categorized under 'Regulatory Filings' (RNS) as they represent specific corporate actions that do not fit into the other specialized categories like M&A, Dividends, or Insider Dealing.
2023-12-27 Korean
타법인주식및출자증권취득결정
M&A Activity Classification · 100% confidence The document is a formal regulatory filing titled '타법인주식및출자증권취득결정' (Decision to Acquire Shares and Equity Securities of Another Corporation). It details the acquisition of shares in 'Canaria Bio' by 'AdBiotech', including the number of shares, acquisition price, purpose, and board resolution details. This is a standard corporate disclosure regarding investment activity and capital allocation, which falls under the 'Regulatory Filings' category as it is a specific material event disclosure required by financial regulators.
2023-12-18 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement regarding the setting of a record date for the shareholder register, specifically for the purpose of holding an upcoming Annual General Meeting (AGM). It is a standard corporate notice regarding shareholder rights and meeting preparation, which falls under general regulatory announcements as it does not contain the full proxy materials or the meeting presentation itself.
2023-12-15 Korean
분기보고서 (2023.09)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for the company '주식회사 애드바이오텍' covering the period from January 1, 2023, to September 30, 2023. It contains detailed financial information, business operations, and management disclosures, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2023
2023-11-13 Korean
반기보고서 (2023.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-Annual Report) for the company '주식회사 애드바이오텍' covering the period from 2023-01-01 to 2023-06-30. It contains detailed financial information, business operations, and management analysis, which fits the definition of an Interim/Quarterly Report (IR). H1 2023
2023-08-11 Korean
[기재정정]주요사항보고서(타법인주식및출자증권양도결정)
M&A Activity Classification · 100% confidence The document is a formal regulatory filing submitted to the Korea Exchange (KRX) regarding the 'Decision to Transfer Shares and Securities of Other Corporations' (타법인 주식 및 출자증권 양도결정). It is a correction report (정정신고) detailing changes to previously reported share transfer amounts and transaction details. Since this is a specific regulatory disclosure regarding corporate asset/share transactions that does not fit into categories like M&A (which usually implies a merger/acquisition of the company itself) or share buybacks (which would be POS), it is best classified as a general regulatory filing.
2023-06-21 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.